Advertisement Ceapro licenses process technology from University of Alberta - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ceapro licenses process technology from University of Alberta

Ceapro has announced the signing of a licensing and development agreement with the University of Alberta for the rights related to a technology entitled: ‘Formation of Micro/Nanoparticles and Encapsulation of Bioactives Using Supercritical Fluid Technology’.

Ceapro president and CEO Gilles Gagnon said that the signing of this Agreement is a significant milestone for our Company since this technology would allow the development, production and commercialization of powder formulations that could be used as active ingredients in large markets like functional food, nutraceuticals and pharmaceuticals, a vision that we have expressed over the last two years.

This Technology was invented by Dr Feral Temelli from Department of Agricultural, Food & Nutritional Science of the University of Alberta, and Ceapro senior researcher Dr Bernhard Seifried.

The technology is called ‘PGX Technology’, a novel spray drying technique for processing water-soluble biopolymers, including oat beta glucan, utilizing the unique and tuneable properties of Pressurized Gas eXpanded liquids.

PGX Technology is a platform that can produce numerous morphologies of biopolymers ranging from fine fibres to granular powder, which are highly water soluble and could find commercial success in a wide range of industries including functional foods, nutraceuticals, cosmeceuticals, and pharmaceutical products.

This technology operates at lower temperatures than conventional spray drying allowing incorporation of thermosensitive bioactives as well.